Form 4 for AORT ARTIVION, INC.
Accepted 2025-11-24 00:00:00 ET · period of report 2025-11-21 · accession 0001628280-25-053859 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DM | 2025-11-24 | 2025-11-21 | AORT | Stanton Marshall S. | SVP, Clinical, MD Affair | S - Sale+OE | $45.04 | -47.4K | 44.8K | -51% | -$2.13M |
| DM | 2025-11-24 | 2025-11-21 | AORT | Stanton Marshall S. | SVP, Clinical, MD Affair | M - OptEx | $14.21 | +47.4K | 71.8K | +194% | +$673.0K |
| DM | 2025-11-24 | 2025-11-21 | AORT | Stanton Marshall S. | SVP, Clinical, MD Affair | M - OptEx | $0.00 | -47.4K | 0 | -100% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2025-11-21 | S | D | 18,705 | $44.91 | 53,123 | D | — | — | (F3) Reflects weighted average price. Range of prices were between $44.26 to $45.255. The reporting person will provide upon request by the Commission staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price. |
| 2 | Common | Common Stock | 2025-11-21 | S | D | 8,370 | $45.35 | 44,753 | D | — | — | (F4) Reflects weighted average price. Range of prices were between $45.26 to $45.53. The reporting person will provide upon request by the Commission staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price. |
| 3 | Common | Common Stock | 2025-11-21 | M | A | 20,301 | $18.44 | 65,054 | D | — | — | |
| 4 | Common | Common Stock | 2025-11-21 | S | D | 14,586 | $44.92 | 50,468 | D | — | — | (F1) Reflects weighted average price. Range of prices were between $44.26 to $45.25. The reporting person will provide upon request by the Commission staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price. |
| 5 | Common | Common Stock | 2025-11-21 | S | D | 5,715 | $45.35 | 44,753 | D | — | — | (F2) Reflects weighted average price. Range of prices were between $45.26 to $45.54. The reporting person will provide upon request by the Commission staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price. |
| 6 | Common | Common Stock | 2025-11-21 | M | A | 27,075 | $11.03 | 71,828 | D | — | — | |
| 7 | Derivative | Stock Options (Right to buy) | 2025-11-21 | M | D | 20,301 | $0.00 | 0 | D | $18.44 · 2023-02-23 to 2029-02-23 | 20,301 Common Stock | (F5) Stock option vests 33 1/3% per year beginning on the first anniversary of the grant date. The first exercisable date was February 23, 2023. |
| 8 | Derivative | Stock Options (Right to buy) | 2025-11-21 | M | D | 27,075 | $0.00 | 0 | D | $11.03 · 2023-11-08 to 2029-11-08 | 27,075 Common Stock | (F6) Stock option vests 33 1/3% per year beginning on the first anniversary of the grant date. The first exercisable date was November 8, 2023. |